Annals of medicine and surgery (2012) · 2026
Vitamin C for the management of COVID-19: a systematic review and meta-analysis of randomized controlled trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abid Hassaan, Mushtaq Iqra, Munir Amna Bint I, Shakil Jaweria, Vinjamuri Saketh, Tadasare Niraj, Kiran Fnu, Muhammad Wali Mirza Agha, Fatima Khidri Feriha, Shahid Amna, Ayyan Muhammad, Ehsan Muhammad, Cheema Huzaifa Ahmad, Alsubari Asma'a Munasar Ali, Sahra Syeda, Siddiqi Nabeela Iffat
Аннотация
BACKGROUND: Vitamin C is a vital nutrient that functions as an antioxidant and is important as a co-factor and regulator of several immune system pathways. The role of vitamin C in the treatment of COVID-19 is largely debatable. We conducted this meta-analysis to evaluate the efficacy and safety of vitamin C in the treatment of COVID-19.
METHODS: We searched several electronic databases from inception to March 2023 to retrieve randomized controlled trials on the use of vitamin C for COVID-19. RevMan 5.4 was used to calculate risk ratios (RRs) and mean differences (MDs) along with confidence intervals (95% CI) using a random-effects model.
RESULTS: We included nine randomized controlled trials in our meta-analysis. Vitamin C did not reduce the all-cause mortality in patients with COVID-19 compared to the standard treatment (RR 0.92, 95% CI: 0.83-1.02; I 2 = 1%). Vitamin C was found to be associated with a similar incidence of ventilation in COVID-19 patients when compared to standard treatment (RR 0.98, 95% CI: 0.87-1.11, I 2 = 0%). There were no significant differences between both groups regarding the incidence of hospitalization (RR 1.00, 95% CI: 0.98-1.02; I 2 = 0%), incidence of recovery (RR 1.57, 95% CI: 0.45-5.50; I 2 = 52%), hospital mortality (RR 0.68, 95% CI: 0.44-1.06; I 2 = 0%) and length of hospital stay (MD -0.63, 95% CI: -3.04 to 1.78; I 2 = 81%).
CONCLUSION: Vitamin C administration did not reduce all-cause mortality in COVID-19 patients. Additional studies are required to evaluate the role of vitamin C in the prevention and treatment of COVID-19 especially in ICU patients.
METHODS: We searched several electronic databases from inception to March 2023 to retrieve randomized controlled trials on the use of vitamin C for COVID-19. RevMan 5.4 was used to calculate risk ratios (RRs) and mean differences (MDs) along with confidence intervals (95% CI) using a random-effects model.
RESULTS: We included nine randomized controlled trials in our meta-analysis. Vitamin C did not reduce the all-cause mortality in patients with COVID-19 compared to the standard treatment (RR 0.92, 95% CI: 0.83-1.02; I 2 = 1%). Vitamin C was found to be associated with a similar incidence of ventilation in COVID-19 patients when compared to standard treatment (RR 0.98, 95% CI: 0.87-1.11, I 2 = 0%). There were no significant differences between both groups regarding the incidence of hospitalization (RR 1.00, 95% CI: 0.98-1.02; I 2 = 0%), incidence of recovery (RR 1.57, 95% CI: 0.45-5.50; I 2 = 52%), hospital mortality (RR 0.68, 95% CI: 0.44-1.06; I 2 = 0%) and length of hospital stay (MD -0.63, 95% CI: -3.04 to 1.78; I 2 = 81%).
CONCLUSION: Vitamin C administration did not reduce all-cause mortality in COVID-19 patients. Additional studies are required to evaluate the role of vitamin C in the prevention and treatment of COVID-19 especially in ICU patients.